Glenmark Pharmaceuticals Limited (NSE:GLENMARK) has disclosed that it will conduct an earnings call on unaudited financial results for the quarter ended June 30, 2026, on Monday, August 3, 2026, from 8:30 am to 9:30 am IST. The company filed this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, on July 21, 2026. Investors and analysts can participate via telephone dial-in numbers provided across multiple geographies or pre-register online through the company's designated contact.
Key Highlights
- Glenmark Pharmaceuticals will hold its Q1 FY27 earnings call on August 3, 2026, from 8:30 am to 9:30 am IST to discuss unaudited financial results for the quarter ended June 30, 2026.
- Universal access dial-in number for India participants is +91 22 6280 1298 and +91 22 7115 8199, with international lines available for USA, UK, Singapore, and Hong Kong.
- Online pre-registration facility is available for investors and analysts who wish to participate in the earnings call without using dial-in numbers.
- Utkarsh Gandhi, Company contact, can be reached at [email protected] or +91 22 4018 9232 for any clarification regarding the call.
- The company has filed this intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, as mandated for material corporate announcements.
- Rashmi Khandelwal, Company Secretary and Compliance Officer (ACS 28839), has issued the disclosure on behalf of Glenmark Pharmaceuticals Limited.
About the Company
Glenmark Pharmaceuticals Limited is a globally diversified pharmaceutical company headquartered in Mumbai, with registered office at B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026. The company operates across multiple therapeutic areas and markets, offering branded formulations, generic pharmaceuticals, and active pharmaceutical ingredients to customers across India and international markets. Glenmark is listed on both the National Stock Exchange (NSE) under the ticker GLENMARK and the Bombay Stock Exchange (BSE) with scrip code 532296. The company's CIN is L24299MH1977PLC019982, and its ISIN is INE935A01035. Glenmark maintains its corporate headquarters at Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, from where it conducts its corporate operations and investor relations activities.
Announcement in Detail
Glenmark Pharmaceuticals has formally notified both the National Stock Exchange of India Limited and BSE Limited of an upcoming earnings call scheduled for Monday, August 3, 2026, between 8:30 am and 9:30 am IST. The call will focus on discussion of unaudited financial results for the quarter ended June 30, 2026, representing the first quarter of fiscal year 2027. The disclosure was submitted on July 21, 2026, at 15:29:51 hours, under the company's reference number 32/26-27, in compliance with Regulation 30 and Schedule III Part A of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The company has provided multiple participation channels to facilitate access for domestic and international participants. Domestic investors and analysts can dial +91 22 6280 1298 or +91 22 7115 8199 to join the call. International participants have access to dedicated lines: USA participants can reach 1 866 746 2133, UK participants 0 808 101 1573, Singapore participants 800 101 2045, and Hong Kong participants 800 964 448. In addition to telephonic participation, the company has enabled an online pre-registration facility for participants who prefer to register in advance rather than using dial-in numbers directly.
For any inquiries regarding the earnings call, participants have been directed to contact Utkarsh Gandhi via email at [email protected] or by telephone at +91 22 4018 9232. The formal intimation was executed by Rashmi Khandelwal, Company Secretary and Compliance Officer of Glenmark Pharmaceuticals Limited, who holds ACS membership number 28839.
Impact on Investors
The earnings call represents a scheduled opportunity for existing and prospective shareholders, institutional investors, and financial analysts to obtain direct communication on the company's operational and financial performance for the first quarter of FY27. By providing multiple dial-in numbers across geographies and an online pre-registration facility, the company has created accessibility across different investor bases. The call allows participants to hear management commentary on quarter-ended results and pose questions directly to company leadership, providing transparency on business performance, strategic initiatives, and financial metrics during a period that includes the first quarter of a new fiscal year. Investors will note that this disclosure satisfies the company's regulatory obligation under SEBI Listing Obligations and Disclosure Requirements Regulations to notify market participants of events material to stakeholder decision-making.
The filing shows that the company follows structured investor communication protocols by pre-announcing earnings calls in compliance with exchange regulations. For investors seeking to understand quarterly operational performance and financial trends, this earnings call provides a formal platform for management interaction. The specificity of date, time, and contact channels indicates a well-organised investor relations framework. Investors should note that the results to be discussed will be unaudited figures for the quarter ended June 30, 2026, which differ from audited annual results and represent preliminary quarterly performance metrics subject to potential revision upon audit completion.
Sector / Market Context
Glenmark Pharmaceuticals operates within India's pharmaceutical sector, which comprises branded formulations, generics manufacturers, and active pharmaceutical ingredient producers serving both domestic and export markets. The Indian pharmaceutical industry has historically maintained strong growth dynamics, with companies regularly conducting quarterly earnings calls as part of standard investor relations practice and exchange compliance requirements. Quarterly earnings disclosures and subsequent earnings calls represent standard practice across listed pharmaceutical companies in India, enabling market participants to track operational performance and assess business trajectory across quarters. The conduct of earnings calls aligned with unaudited quarterly results reflects industry-standard transparency practices adopted by SEBI-listed pharmaceutical companies to maintain investor confidence and ensure timely dissemination of material financial information.